A new MS cell therapy uses a patient's own red blood cells to retrain the immune system, helping protect myelin and reduce ...

Novartis shares rose after the drugmaker reported positive results in two late-stage trials from its new pill for the most ...

MRI brain network patterns differed in MS patients, with distinct changes linked to disability, cognition, and disease ...

Results from a small trial suggest a modified virus can instruct the immune system to wipe out disease-causing cells.

Wearable accelerometer-based real-life walking speed monitoring can track disability progression earlier and more often than ...

U.S. Multiple Sclerosis Drugs Market to Reach USD 20.89 Billion and Europe USD 15.51 Billion by 2035 as Monoclonal Antibody ...

A personal reflection on living with multiple sclerosis, drawing parallels to the practice of hobbling horses, and finding ...

Novartis (NVS) stock gains as late-stage trials for hives therapy Rhapsido meet main goals in patients with multiple sclerosis. Read more here.

The oral drug remibrutinib cut relapse rates in patients with relapsing multiple sclerosis, beating a rival treatment in both ...

LONDON, Sept 1 (Reuters) - Swiss drugmaker Novartis said on Tuesday that its oral drug, remibrutinib, met the main goals in ...

The mom of two was diagnosed with MS in 2020 ...